Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Editas Medicine's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IFK vs BNTC, PBYI, EVMN: FCF Margin % Comparison
For the Biotechnology subindustry, Editas Medicine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Editas Medicine's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (LTS:0IFK) has a FCF Margin % of -249.57% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #615 out of 956 companies in the Biotechnology industry, placing it in the top 64.3%.
Is Editas Medicine's FCF Margin % too high?
Editas Medicine's current FCF Margin % is -249.57%. Based on the distribution chart, Editas Medicine ranks #615 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's FCF Margin % compare to BNTC and PBYI?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #615 out of 956 companies for FCF Margin %. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Editas Medicine and its competitors. Editas Medicine's current FCF Margin % is -249.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (LTS:0IFK) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.27, compared to a current price of $2.82 — trading 24.3% above its estimated fair value. The current FCF Margin % is -249.57%. Editas Medicine's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Editas Medicine (LTS:0IFK), the current FCF Margin % is -249.57% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (LTS:0IFK) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.82 is trading 24.3% above its estimated GF Value™ of $2.27.
GuruFocus considers Editas Medicine to be Modestly Overvalued.
Key valuation signals for LTS:0IFK:
FCF Margin %: -249.57%
GF Value™: $2.27 vs. price of $2.82 (24.3% above fair value)
No single metric tells the full story. See the LTS:0IFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
58GF Score
Get the complete analysis for LTS:0IFK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IFK has been successfully added to your 
